Researchers will investigate a novel therapeutic target for mammary gland cancer in dogs.

Researchers will create an optical map of the canine genome, an important tool to identify gaps and missing structural components in the current canine genome assembly.

Researchers will determine if genetic factors and co-administered drugs influence the clinical effectiveness of tramadol, a commonly used pain-relief drug in dogs.

Researchers will investigate the role of a small protein released in response to inflammation as a potential new therapy target to control itch and inflammation in dogs with chronic, relapsing allergic skin disease.

Researchers will investigate the effectiveness of an oral vitamin D supplement to improve vitamin D levels in dogs, and explore its potential benefit as an adjunct therapy in dogs with cancer.

Researchers will search for genetic mutations associated with mitral valve disease, a common heart condition in small breed dogs, to improve disease management and prevention.

Researchers will evaluate the efficacy of a vaccine for visceral leishmaniasis, a parasitic disease, in United States foxhounds.

Researchers are studying a group of 80 dogs with osteosarcoma to generate comparison data for ongoing and future studies of new chemotherapeutic agents.

Researchers are evaluating the effectiveness of oral rapamycin as an adjunct, postsurgery therapy to combat cancer spread (metastasis) in client-owned dogs.

This grant supports the advanced training of two aspiring veterinary pathologists who will assist with the analysis of tissue samples collected from dogs enrolled in Morris Animal Foundation's Golden Retriever Lifetime Study.